Switch to: References

Add citations

You must login to add citations.
  1. Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform.Marc A. Rodwin - 2012 - Journal of Law, Medicine and Ethics 40 (3):511-522.
    When physicians' conflicts of interest arise from ties with drug firms, we should shift our focus to the pharmaceutical industry and improper dependencies that cause institutional corruption. This article analyzes eight forms of improper dependencies on pharma and proposes reforms.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   13 citations  
  • Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines.Lisa Cosgrove & Emily E. Wheeler - 2013 - Journal of Law, Medicine and Ethics 41 (3):644-653.
    The possibility that industry is exerting an undue influence on the culture of medicine has profound implications for the profession's public health mission. Policy analysts, investigative journalists, researchers, and clinicians have questioned whether academic-industry relationships have had a corrupting effect on evidence-based medicine. Psychiatry has been at the heart of this epistemic and ethical crisis in medicine. This article examines how commercial entities, such as pharmaceutical companies, influence psychiatric taxonomy and treatment guidelines. Using the conceptual framework of institutional corruption, we (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  • Rooting Out Institutional Corruption to Manage Inappropriate Off‐Label Drug Use.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):654-664.
    Prescribing drugs for uses that the FDA has not approved — off-label drug use — can sometimes be justified but is typically not supported by substantial evidence of effectiveness. At the root of inappropriate off-label drug use lie perverse incentives for pharmaceutical firms and flawed oversight of prescribing physicians. Typical reform proposals such as increased sanctions for manufacturers might reduce the incidence of unjustified off-label use, but they do not remove the source of the problem. Public policy should address the (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  • Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan.Marc A. Rodwin - 2011 - Journal of Law, Medicine and Ethics 39 (4):662-670.
    This article compares the means that the United States, France, and Japan use to oversee pharmaceutical industry-physician financial relationships. These countries rely on professional and/or industry ethical codes, anti-kickback laws, and fair trade practice laws. They restrict kickbacks the most strictly, allow wide latitude on gifts, and generally permit drug firms to fund professional activities and associations. Consequently, to avoid legal liability, drug firms often replace kickbacks with gifts and grants. The paper concludes by proposing reforms that address problems that (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  • Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On.Sergio Sismondo - 2013 - Journal of Law, Medicine and Ethics 41 (3):635-643.
    The pharmaceutical industry, in its marketing efforts, often turns to “key opinion leaders” or “KOLs” to disseminate scientific information. Drawing on the author's fieldwork, this article documents and examines the use of KOLs in pharmaceutical companies’ marketing efforts. Partly due to the use of KOLs, a small number of companies with well-defined and narrow interests have inordinate influence over how medical knowledge is produced, circulated, and consumed. The issue here, as in many other cases of institutional corruption, is that a (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   19 citations  
  • Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform.Marc A. Rodwin - 2012 - Journal of Law, Medicine and Ethics 40 (3):511-522.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   12 citations  
  • Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines.Lisa Cosgrove & Emily E. Wheeler - 2013 - Journal of Law, Medicine and Ethics 41 (3):644-653.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  • Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):654-664.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   10 citations  
  • Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan.Marc A. Rodwin - 2011 - Journal of Law, Medicine and Ethics 39 (4):662-670.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations